Author: "Pecori, E." / Search Limiters: Available in Library Collection - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Pecori, E."' showing total 24 results

Start Over Author "Pecori, E." Search Limiters Available in Library Collection

24 results on '"Pecori, E."'

1. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients

Author: Massimino, M, Sunyach, M, Barretta, F, Gandola, L, Garegnani, A, Pecori, E, Spreafico, F, Bonneville-Levard, A, Meyronet, D, Mottolese, C, Boschetti, L, Biassoni, V, Schiavello, E, Giussani, C, Carrabba, G, Diletto, B, Pallotti, F, Stefini, R, Ferrari, A, Terenziani, M, Casanova, M, Luksch, R, Meazza, C, Podda, M, Chiaravalli, S, Puma, N, Bergamaschi, L, Morosi, C, Calareso, G, Giangaspero, F, Antonelli, M, Buttarelli, F, Frappaz, D, Massimino M., Sunyach M. P., Barretta F., Gandola L., Garegnani A., Pecori E., Spreafico F., Bonneville-Levard A., Meyronet D., Mottolese C., Boschetti L., Biassoni V., Schiavello E., Giussani C., Carrabba G., Diletto B., Pallotti F., Stefini R., Ferrari A., Terenziani M., Casanova M., Luksch R., Meazza C., Podda M., Chiaravalli S., Puma N., Bergamaschi L., Morosi C., Calareso G., Giangaspero F., Antonelli M., Buttarelli F. R., Frappaz D., Massimino, M, Sunyach, M, Barretta, F, Gandola, L, Garegnani, A, Pecori, E, Spreafico, F, Bonneville-Levard, A, Meyronet, D, Mottolese, C, Boschetti, L, Biassoni, V, Schiavello, E, Giussani, C, Carrabba, G, Diletto, B, Pallotti, F, Stefini, R, Ferrari, A, Terenziani, M, Casanova, M, Luksch, R, Meazza, C, Podda, M, Chiaravalli, S, Puma, N, Bergamaschi, L, Morosi, C, Calareso, G, Giangaspero, F, Antonelli, M, Buttarelli, F, Frappaz, D, Massimino M., Sunyach M. P., Barretta F., Gandola L., Garegnani A., Pecori E., Spreafico F., Bonneville-Levard A., Meyronet D., Mottolese C., Boschetti L., Biassoni V., Schiavello E., Giussani C., Carrabba G., Diletto B., Pallotti F., Stefini R., Ferrari A., Terenziani M., Casanova M., Luksch R., Meazza C., Podda M., Chiaravalli S., Puma N., Bergamaschi L., Morosi C., Calareso G., Giangaspero F., Antonelli M., Buttarelli F. R., and Frappaz D.
Abstract: Introduction: Medulloblastoma is the most common malignant brain tumor in children, but accounts for only 1% of brain cancers in adults. For standard-risk pediatric medulloblastoma, current therapy includes craniospinal irradiation (CSI) at reduced doses (23.4 Gy) associated with chemotherapy. Whereas most same-stage adult patients are still given CSI at 36 Gy, with or without chemotherapy, we report here on our use of reduced-dose CSI associated with chemotherapy for older patients. Methods: We gathered non-metastatic patients over 18 years old (median age 28 years, range 18–48) with minimal or no residual disease after surgery, no negative histological subtypes, treated between 1996–2018 at the Centre Léon Bérard (Lyon) and the INT (Milano). A series of 54 children with similar tumors treated in Milano was used for comparison. Results: Forty-four adults were considered (median follow-up 101 months): 36 had 23.4 Gy of CSI, and 8 had 30.6 Gy, plus a boost to the posterior fossa/tumor bed; 43 had chemotherapy as all 54 children, who had a median 83-month follow-up. The PFS and OS were 82.2 ± 6.1% and 89 ± 5.2% at 5 years, and 78.5 ± 6.9% and 75.2 ± 7.8% at ten, not significantly different from those of the children. CSI doses higher than 23.4 Gy did not influence PFS. Female adult patients tended to have a better outcome than males. Conclusion: The results obtained in our combined series are comparable with, or even better than those obtained after high CSI doses, underscoring the need to reconsider this treatment in adults.
Published: 2020

2. Neurological Symptom Improvement After Re-Irradiation in Patients With Diffuse Intrinsic Pontine Glioma: A Retrospective Analysis of the SIOP-E-HGG/DIPG Project

Author: Chavaz L, Janssens GO, Bolle S, Mandeville H, Ramos-Albiac M, Van Beek K, Benghiat H, Hoeben B, Morales-La Madrid A, Seidel C, Kortmann RD, Hargrave D, Gandola L, Pecori E, van Vuurden DG, Biassoni V, Massimino M, Kramm CM, and von Bueren AO
Subjects: re-irradiation (re-RT), child, diffuse intrinsic pontine glioma (DIPG), adolescent, radiotherapy
Abstract: PURPOSE: The aim of this study is to investigate the spectrum of neurological triad improvement in patients with diffuse intrinsic pontine glioma (DIPG) treated by re-irradiation (re-RT) at first progression. METHODS: We carried out a re-analysis of the SIOP-E retrospective DIPG cohort by investigating the clinical benefits after re-RT with a focus on the neurological triad (cranial nerve deficits, ataxia, and long tract signs). Patients were categorized as "responding" or "non-responding" to re-RT. To assess the interdependence between patients' characteristics and clinical benefits, we used a chi-square or Fisher's exact test. Survival according to clinical response to re-RT was calculated by the Kaplan-Meier method. RESULTS: As earlier reported, 77% (n = 24/31) of patients had any clinical benefit after re-RT. Among 25/31 well-documented patients, 44% (n = 11/25) had improvement in cranial nerve palsies, 40% (n = 10/25) had improvement in long-tract signs, and 44% (11/25) had improvement in cerebellar signs. Clinical benefits were observed in at least 1, 2, or 3 out of 3 symptoms of the DIPG triad, in 64%, 40%, and 24%, respectively. Patients irradiated with a dose =20 Gy versus
Published: 2022

3. P06.01 Pediatric non-pontine diffuse midline glioma H3K27M mutant: a monoinstitutional experience

Author: Schiavello, E, primary, Biassoni, V, additional, De Cecco, L, additional, Pecori, E, additional, Filippo, S, additional, Gandola, L, additional, and Massimino, M, additional
Published: 2021
Full Text: View/download PDF

4. P14.77 Reduced dose craniospinal irradiation (CSI) is feasible for standard risk adult medulloblastoma (MBL) patients similarly to pediatric population

Author: Massimino, M, primary, Sunyach, M, additional, Gandola, L, additional, Pecori, E, additional, Spreafico, F, additional, Bonneville Levard, A, additional, Biassoni, V, additional, Schiavello, E, additional, Diletto, B, additional, Stefini, R, additional, and Frappaz, D, additional
Published: 2019
Full Text: View/download PDF

5. Pediatric intracranial ependymoma: correlating signs and symptoms at recurrence with outcome in the second prospective AIEOP protocol follow-up

Author: Massimino, M, Barretta, F, Modena, P, Giangaspero, F, Chiapparini, L, Erbetta, A, Boschetti, L, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Viscardi, E, Scarzello, G, Mascarin, M, Quaglietta, L, Cinalli, G, Genitori, L, Peretta, P, Mussano, A, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Tornesello, A, La Spina, M, Buttarelli, F, Ruggiero, A, Caldarelli, M, Poggi, G, Gandola, L, Garrè, ML, Marras, CE, Buttarelli, FR, Massimino, M, Barretta, F, Modena, P, Giangaspero, F, Chiapparini, L, Erbetta, A, Boschetti, L, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Viscardi, E, Scarzello, G, Mascarin, M, Quaglietta, L, Cinalli, G, Genitori, L, Peretta, P, Mussano, A, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Tornesello, A, La Spina, M, Buttarelli, F, Ruggiero, A, Caldarelli, M, Poggi, G, Gandola, L, Garrè, ML, Marras, CE, and Buttarelli, FR
Abstract: Purpose: The aims of patients’ radiological surveillance are to: ascertain relapse; apply second-line therapy; accrue patients in phase 1/2 protocols if second-line therapy is not standardized/curative; and assess/treat iatrogenic effects. To lessen the emotional and socioeconomic burdens for patients and families, we ideally need to establish whether scheduled radiological surveillance gives patients a better outcome than waiting for symptoms and signs to appear. Methods: We analyzed a prospective series of 160 newly-diagnosed and treated pediatric/adolescent patients with intracranial ependymoma, comparing patients with recurrent disease identified on scheduled MRI (the RECPT group; 34 cases) with those showing signs/symptoms of recurrent disease (the SYMPPT group; 16 cases). The median follow-up was 67 months. Results: No significant differences emerged between the two groups in terms of gender, age, tumor grade/site, shunting, residual disease, or type of relapse (local, distant, or concomitant). The time to relapse (median 19 months; range 5–104) and the MRI follow-up intervals did not differ between the SYMPPT and RECPT groups. The presence of signs/symptoms was an unfavorable factor for overall survival (OS) after recurrence (5-year OS: 8% vs. 37%, p = 0.001). On multivariable analysis, an adjusted model confirmed a significantly worse OS in the SYMPPT than in the RECPT patients. Conclusions: Symptomatic relapses carried a significantly worse survival for ependymoma patients than recurrences detected by MRI alone. It would therefore be desirable to identify recurrences before symptoms develop. Radiological follow-up should be retained in ependymoma patient surveillance because there is a chance of salvage treatment for relapses found on MRI
Published: 2018

6. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group

Author: Janssens, G.O., Gandola, L., Bolle, S., Mandeville, H., Ramos-Albiac, M., Beek, K., Benghiat, H., Hoeben, B.A., Morales la Madrid, A., Kortmann, R.D., Hargrave, D., Menten, J., Pecori, E., Biassoni, V., Bueren, A.O. von, Vuurden, D.G. van, Massimino, M., Sturm, D., Peters, M., Kramm, C.M., Janssens, G.O., Gandola, L., Bolle, S., Mandeville, H., Ramos-Albiac, M., Beek, K., Benghiat, H., Hoeben, B.A., Morales la Madrid, A., Kortmann, R.D., Hargrave, D., Menten, J., Pecori, E., Biassoni, V., Bueren, A.O. von, Vuurden, D.G. van, Massimino, M., Sturm, D., Peters, M., and Kramm, C.M.
Abstract: Item does not contain fulltext, BACKGROUND: Overall survival (OS) of patients with diffuse intrinsic pontine glioma (DIPG) is poor. The purpose of this study is to analyse benefit and toxicity of re-irradiation at first progression. METHODS: At first progression, 31 children with DIPG, aged 2-16 years, underwent re-irradiation (dose 19.8-30.0 Gy) alone (n = 16) or combined with systemic therapy (n = 15). At initial presentation, all patients had typical symptoms and characteristic MRI features of DIPG, or biopsy-proven high-grade glioma. An interval of >/=3 months after upfront radiotherapy was required before re-irradiation. Thirty-nine patients fulfilling the same criteria receiving radiotherapy at diagnosis, followed by best supportive care (n = 20) or systemic therapy (n = 19) at progression but no re-irradiation, were eligible for a matched-cohort analysis. RESULTS: Median OS for patients undergoing re-irradiation was 13.7 months. For a similar median progression-free survival after upfront radiotherapy (8.2 versus 7.7 months; P = .58), a significant benefit in median OS (13.7 versus 10.3 months; P = .04) was observed in favour of patients undergoing re-irradiation. Survival benefit of re-irradiation increased with a longer interval between end-of-radiotherapy and first progression (3-6 months: 4.0 versus 2.7; P < .01; 6-12 months: 6.4 versus 3.3; P = .04). Clinical improvement with re-irradiation was observed in 24/31 (77%) patients. No grade 4-5 toxicity was recorded. On multivariable analysis, interval to progression (corrected hazard ratio = .27-.54; P < .01) and re-irradiation (corrected hazard ratio = .18-.22; P < .01) remained prognostic for survival. A risk score (RS), comprising 5 categories, was developed to predict survival from first progression (ROC: .79). Median survival ranges from 1.0 month (RS-1) to 6.7 months (RS-5). CONCLUSIONS: The majority of patients with DIPG, responding to upfront radiotherapy, do benefit of re-irradiation with acceptable tolerability.
Published: 2017

7. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma

Author: Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, Gandola, L, GIUSSANI, CARLO GIORGIO, Gandola, L., Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, Gandola, L, GIUSSANI, CARLO GIORGIO, and Gandola, L.
Abstract: Background This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). Methods WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. Results From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. Conclusions In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.
Published: 2016

8. Mid-trimester fetal-placental velocimetry response to nifedipine may predict early the onset of pre-eclampsia

Author: Cobellis, L., Antonio De Luca, Pecori, E., Mastrogiacomo, A., Di Pietto, L., Iannella, I., Fornaro, F., Scaffa, C., Cobellis, G., Colacurci, N., Cobellis, Luigi, DE LUCA, Antonio, Pecori, E, Mastrogiacomo, A, DI PIETRO, L, Iannella, I, Fornaro, F, Scaffa, C, Cobellis, G, and Colacurci, Nicola
Subjects: fetal growth restriction, Fetus, fetalplacental, Nifedipine, Pre-Eclampsia, placenta, Pregnancy Trimester, Second, Hypertension, Doppler, Humans, Female, pregnancy
Abstract: The effect of nifedipine on fetal-placental blood flow at 22-24 weeks in patients with pregnancy-induced hypertension (PIH) was evaluated. Twenty patients with PIH were submitted to the Doppler evaluation of fetal-placental perfusion at 22-24 weeks. The systo-diastolic (SID) ratio and the pulsatility index (PI) of uterine, umbilical and middle cerebral arteries and systemic blood pressure were recorded before and 7 days after nifedipine administration (10 mg/ per os 3 times/day until delivery). Statistical analysis was performed with paired and unpaired t-test and the two-tailed Fisher exact test. Nifedipine significantly (p0.05) decreased the mean systolic pressure in all patients (from 146 to 135 mmHg): 8 patients developed pre-eclampsia (PE) complicated by fetal growth restriction (FGR) (PE group), whilst the remaining were only affected by PIH (PIH group). The gestational age at delivery, neonatal birthweight and 1- and 5-min Apgar scores were significantly (p0.001) lower in PE than in PIH women. Nifedipine treatment significantly changed the PI and S/D ratio (mean +/- SEM) of the uterine (PI from 0.66 +/- 0.01 to 0.51 + 0.01; SID ratio: from 2.00 +/- 0.09 to 1.79 + 0.05) and umbilical (PI: from 1.55 +/- 0.04 to 1.40 +/- 0.02; S/D ratio: from 2.45 +/- 0.09 to 2.31+/- 0.09) arteries and the middle cerebral PI (from 1.45 +/- 0.03 to 1.61 +/- 0.01) artery only in PIH, but not in PE patients. Fetal-placental blood flow changes after nifedipine may early identify patients at risk of PE.
Published: 2006

9. Determinants of adenomyosis in women who underwent hysterectomy for benign gynecological conditions: results from a prospective multicentric study in Italy

Author: Parazzini, F, Mais, V, Cipriani, S, Busacca, M, Venturini, P, Ciavattini, A, Baiocchi, R, Goteri, G, Bertivagni, E, Biggio, A, Muriana, Palomba, S, Zullo, F, Bianchi, A, Martinello, R, Bracco, Gl, Rizzitello, F, Coccia, E, Meroni, N, Radaelli, U, Spreafico, C, Odorizzi, Mp, Bertazzoli, E, Cannata, L, Pieroni, G, Vizza, E, Cosmaggioni, I, Pittino, M, Del Frate, G, Trossarelli, Gf, Chiapparo, F, Beretta, P, Ghezzi, F, Cromi, A, Uccella, S, Piccione, E, Di Ciacci, S, Petropolli, A, Sesti, F, Micalef, S, Pecori, E, Cobellis, L, Palermo, Mr, Surico, N, Leo, L, Surico, D, Boninfante, G, and Gis, E.
Subjects: endometriosis, medicine.medical_specialty, Cross-sectional study, Epidemiology, medicine.medical_treatment, prevalence, Endometriosis, cross-sectional studies, Abortion, Rate ratio, dysmenorrhea, Adenomyosis, Risk factor, menorrhagia, middle aged, italy, leiomyoma, medicine, 80 and over, risk factors, hysterectomy, Prospective cohort study, humans, Aged, 80 and over, female, pelvic pain, prospective studies, uterine prolapse, aged, adult, Gynecology, Hysterectomy, Obstetrics, business.industry, Pelvic pain, Obstetrics and Gynecology, medicine.disease, Reproductive Medicine, Settore MED/40 - Ginecologia e Ostetricia, medicine.symptom, business
Abstract: Objective We conducted a cross-sectional study on the frequency and risk factors for adenomyosis in women who underwent hysterectomy for benign gynecological conditions. Study design All women who consecutively underwent hysterectomy during the study period for benign gynecological conditions at 18 gynecological departments were eligible for the study. A total of 820 women entered the study. Pathological data were collected prospectically. Results Adenomyosis was identified in 231 women (28.2%, 95% confidence interval, CI, 24.6–32.5). The frequency of adenomyosis was similar in women with indication for surgery fibroids/menorrhagia (143 cases, 28.5%) or genital prolapse (69 cases, 28.2%). The rate ratio (RR) of adenomyosis was 1.9 (95% CI 1.2–2.8) in women reporting one or more induced abortions, in comparison with those reporting no induced abortion. Women with adenomyosis reported more frequently dysmenorrhoea and chronic pelvic pain, but not dyspareunia. Conclusions This study shows that adenomyosis is common in women who undergo hysterectomy and that it is more frequent among women reporting induced abortions dysmenorrhoea and chronic pelvic pain.
Published: 2009

10. EPENDYMOMA

Author: Hoffman, L. M., primary, Donson, A. M., additional, Nakachi, I., additional, Griesinger, A. M., additional, Birks, D. K., additional, Amani, V., additional, Hemenway, M. S., additional, Liu, A. K., additional, Wang, M., additional, Hankinson, T. C., additional, Handler, M. H., additional, Foreman, N. K., additional, Zakrzewska, M., additional, Zakrzewski, K., additional, Fendler, W., additional, Stefanczyk, L., additional, Liberski, P. P., additional, Massimino, M., additional, Gandola, L., additional, Ferroli, P., additional, Valentini, L., additional, Biassoni, V., additional, Garre, M. L., additional, Sardi, I., additional, Genitori, L., additional, Giussani, C., additional, Massimi, L., additional, Bertin, D., additional, Mussano, A., additional, Viscardi, E., additional, Modena, P., additional, Mastronuzzi, A., additional, Barra, S., additional, Scarzello, G., additional, Cinalli, G., additional, Peretta, P., additional, Giangaspero, F., additional, Boschetti, L., additional, Schiavello, E., additional, Calareso, G., additional, Antonelli, M., additional, Pecori, E., additional, Di Meco, F., additional, Migliorati, R., additional, Taborelli, A., additional, Witt, H., additional, Sill, M., additional, Wani, K., additional, Mack, S. C., additional, Capper, D., additional, Pajtler, K., additional, Lambert, S., additional, Tzaridis, T., additional, Milde, T., additional, Northcott, P. A., additional, Kulozik, A. E., additional, Witt, O., additional, Collins, V. P., additional, Ellison, D. W., additional, Taylor, M. D., additional, Kool, M., additional, Jones, D. T. W., additional, Korshunov, A., additional, Ken, A., additional, Pfister, S. M., additional, Makino, K., additional, Nakamura, H., additional, Kuroda, J.-i., additional, Kuratsu, J.-i., additional, Toledano, H., additional, Margolin, Y., additional, Ohali, A., additional, Michowiz, S., additional, Johann, P., additional, Tabori, U., additional, Walker, E., additional, Hawkins, C., additional, Taylor, M., additional, Yaniv, I., additional, Avigad, S., additional, Hoffman, L., additional, Plimpton, S. R., additional, Stence, N. V., additional, Vibhakar, R., additional, Lourdusamy, A., additional, Rahman, R., additional, Ward, J., additional, Rogers, H., additional, Grundy, R., additional, Punchihewa, C., additional, Lee, R., additional, Lin, T., additional, Orisme, W., additional, Dalton, J., additional, Aronica, E., additional, Smith, A., additional, Gajjar, A., additional, Onar, A., additional, Pounds, S., additional, Tatevossian, R., additional, Merchant, T., additional, Ellison, D., additional, Parker, M., additional, Mohankumar, K., additional, Weinlich, R., additional, Phoenix, T., additional, Thiruvenkatam, R., additional, White, E., additional, Gupta, K., additional, Boop, F., additional, Ding, L., additional, Mardis, E., additional, Wilson, R., additional, Downing, J., additional, Gilbertson, R., additional, Speed, D., additional, Gould, T., additional, Consortium, t. I. E., additional, Hoffman, L. M., additional, Griesinger, A., additional, Donson, A., additional, Birks, D., additional, Ohe, N., additional, Yano, H., additional, Nakayama, N., additional, Iwama, T., additional, Wright, K., additional, Hassall, T., additional, Bowers, D. C., additional, Crawford, J., additional, Bendel, A., additional, Fisher, P. G., additional, Klimo, P., additional, Armstrong, G., additional, Qaddoumi, I., additional, Robinson, G., additional, Wetmore, C., additional, Broniscer, A., additional, Chapman, R., additional, Mayne, C., additional, Duane, H., additional, Kilday, J.-P., additional, Coyle, B., additional, Graul-Conroy, A., additional, Hartsell, W., additional, Bragg, T., additional, Goldman, S., additional, Rebsamen, S., additional, Puccetti, D., additional, Salamat, S., additional, Patel, N. J., additional, Gomi, A., additional, Oguma, H., additional, Hayase, T., additional, Kawahara, Y., additional, Yagi, M., additional, Morimoto, A., additional, Wilbur, C., additional, Dunham, C., additional, Mabbott, D., additional, Carret, A.-S., additional, Lafay-Cousin, L., additional, McNeely, P. D., additional, Eisenstat, D., additional, Wilson, B., additional, Johnston, D., additional, Hukin, J., additional, Mynarek, M., additional, Kortmann, R. D., additional, Kaatsch, P., additional, Pietsch, T., additional, Timmermann, B., additional, Fleischhack, G., additional, Benesch, M., additional, Friedrich, C., additional, von Bueren, A. O., additional, Gerber, N. U., additional, Muller, K., additional, Tippelt, S., additional, Warmuth-Metz, M., additional, Rutkowski, S., additional, von Hoff, K., additional, Murugesan, M. K., additional, Poppleton, H., additional, Currle, S., additional, Kranenburg, T., additional, Eden, C., additional, Boulos, N., additional, Dapper, J., additional, Patel, Y., additional, Freeman, B., additional, Shelat, A., additional, Stewart, C., additional, Guy, R., additional, Adamski, J., additional, Huang, A., additional, Bartels, U., additional, Ramaswamy, V., additional, Krishnatry, R., additional, Laperriere, N., additional, Bouffet, E., additional, Araki, A., additional, Chocholous, M., additional, Gojo, J., additional, Dorfer, C., additional, Czech, T., additional, Dieckmann, K., additional, Slavc, I., additional, Haberler, C., additional, Doerner, E., additional, Muehlen, A. z., additional, Kortmann, R., additional, von Buehren, A., additional, Ottensmeier, H., additional, Resch, A., additional, Kwiecien, R., additional, Faldum, A., additional, Kuehl, J., additional, Sabnis, D., additional, Storer, L., additional, Simmonds, L., additional, Blackburn, S., additional, Lowe, J., additional, Kerr, I., additional, Wohlers, I., additional, Goschzik, T., additional, Dreschmann, V., additional, Denkhaus, D., additional, Rahmann, S., additional, Klein-Hitpass, L., additional, Iglesias, M. J. L., additional, Riet, F. G., additional, Dhermain, F. D., additional, Canale, S., additional, Dufour, C., additional, Rose, C. S., additional, Puget, S., additional, Grill, J., additional, Bolle, S., additional, Parkes, J., additional, Davidson, A., additional, Figaji, A., additional, Pillay, K., additional, Kilborn, T., additional, Padayachy, L., additional, Hendricks, M., additional, Van Eyssen, A., additional, Piccinin, E., additional, Lorenzetto, E., additional, Brenca, M., additional, Aldape, K., additional, Cho, Y.-J., additional, Weiss, W., additional, Phillips, J., additional, Jabado, N., additional, Mora, J., additional, Fan, X., additional, Jung, S., additional, Lee, J. Y., additional, Zitterbart, K., additional, French, P., additional, Kros, J. M., additional, Hauser, P., additional, Faria, C., additional, and Pfister, S., additional
Published: 2014
Full Text: View/download PDF

11. HIGH GRADE GLIOMAS AND DIPG

Author: Classen, C. F., primary, William, D., additional, Linnebacher, M., additional, Farhod, A., additional, Kedr, W., additional, Elsabe, B., additional, Fadel, S., additional, Van Gool, S., additional, De Vleeschouwer, S., additional, Koks, C., additional, Garg, A., additional, Ehrhardt, M., additional, Riva, M., additional, Agostinis, P., additional, Graf, N., additional, Yao, T.-W., additional, Yoshida, Y., additional, Zhang, J., additional, Ozawa, T., additional, James, D., additional, Nicolaides, T., additional, Kebudi, R., additional, Cakir, F. B., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Darendeliler, E., additional, Al-Kofide, A., additional, Al-Shail, E., additional, Khafaga, Y., additional, Al-Hindi, H., additional, Dababo, M., additional, Haq, A. U., additional, Anas, M., additional, Barria, M. G., additional, Siddiqui, K., additional, Hassounah, M., additional, Ayas, M., additional, van Zanten, S. V., additional, Jansen, M., additional, van Vuurden, D., additional, Huisman, M., additional, Vugts, D., additional, Hoekstra, O., additional, van Dongen, G., additional, Kaspers, G., additional, Cockle, J., additional, Ilett, E., additional, Scott, K., additional, Bruning-Richardson, A., additional, Picton, S., additional, Short, S., additional, Melcher, A., additional, Benesch, M., additional, Warmuth-Metz, M., additional, von Bueren, A. O., additional, Hoffmann, M., additional, Pietsch, T., additional, Kortmann, R.-D., additional, Eyrich, M., additional, Rutkowski, S., additional, Fruhwald, M. C., additional, Faber, J., additional, Kramm, C., additional, Porkholm, M., additional, Valanne, L., additional, Lonnqvist, T., additional, Holm, S., additional, Lannering, B., additional, Riikonen, P., additional, Wojcik, D., additional, Sehested, A., additional, Clausen, N., additional, Harila-Saari, A., additional, Schomerus, E., additional, Thorarinsdottir, H. K., additional, Lahteenmaki, P., additional, Arola, M., additional, Thomassen, H., additional, Saarinen-Pihkala, U. M., additional, Kivivuori, S.-M., additional, Buczkowicz, P., additional, Hoeman, C., additional, Rakopoulos, P., additional, Pajovic, S., additional, Morrison, A., additional, Bouffet, E., additional, Bartels, U., additional, Becher, O., additional, Hawkins, C., additional, Gould, T. W. A., additional, Rahman, C. V., additional, Smith, S. J., additional, Barrett, D. A., additional, Shakesheff, K. M., additional, Grundy, R. G., additional, Rahman, R., additional, Barua, N., additional, Cronin, D., additional, Gill, S., additional, Lowisl, S., additional, Hochart, A., additional, Maurage, C.-A., additional, Rocourt, N., additional, Vinchon, M., additional, Kerdraon, O., additional, Escande, F., additional, Grill, J., additional, Pick, V. K., additional, Leblond, P., additional, Burzynski, G., additional, Janicki, T., additional, Burzynski, S., additional, Marszalek, A., additional, Ramani, N., additional, Zaky, W., additional, Kannan, G., additional, Morani, A., additional, Sandberg, D., additional, Ketonen, L., additional, Maher, O., additional, Corrales-Medina, F., additional, Meador, H., additional, Khatua, S., additional, Brassesco, M., additional, Delsin, L., additional, Roberto, G., additional, Silva, C., additional, Ana, L., additional, Rego, E., additional, Scrideli, C., additional, Umezawa, K., additional, Tone, L., additional, Kim, S. J., additional, Kim, C.-Y., additional, Kim, I.-A., additional, Han, J. H., additional, Choi, B.-S., additional, Ahn, H. S., additional, Choi, H. S., additional, Haque, F., additional, Layfield, R., additional, Grundy, R., additional, Gandola, L., additional, Pecori, E., additional, Biassoni, V., additional, Schiavello, E., additional, Chiruzzi, C., additional, Spreafico, F., additional, Modena, P., additional, Bach, F., additional, Pignoli, E., additional, Massimino, M., additional, Drogosiewicz, M., additional, Dembowska-Baginska, B., additional, Jurkiewicz, E., additional, Filipek, I., additional, Perek-Polnik, M., additional, Swieszkowska, E., additional, Perek, D., additional, Bender, S., additional, Jones, D. T., additional, Warnatz, H.-J., additional, Hutter, B., additional, Zichner, T., additional, Gronych, J., additional, Korshunov, A., additional, Eils, R., additional, Korbel, J. O., additional, Yaspo, M.-L., additional, Lichter, P., additional, Pfister, S. M., additional, Yadavilli, S., additional, Becher, O. J., additional, Kambhampati, M., additional, Packer, R. J., additional, Nazarian, J., additional, Lechon, F. C., additional, Fowkes, L., additional, Khabra, K., additional, Martin-Retortillo, L. M., additional, Marshall, L. V., additional, Vaidya, S., additional, Koh, D.-M., additional, Leach, M. O., additional, Pearson, A. D., additional, Zacharoulis, S., additional, Schrey, D., additional, Barone, G., additional, Panditharatna, E., additional, Stampar, M., additional, Siu, A., additional, Gordish-Dressman, H., additional, Devaney, J., additional, Hwang, E. I., additional, Chung, A. H., additional, Mittapalli, R. K., additional, Elmquist, W. F., additional, Castel, D., additional, Debily, M.-A., additional, Philippe, C., additional, Truffaux, N., additional, Taylor, K., additional, Calmon, R., additional, Boddaert, N., additional, Le Dret, L., additional, Saulnier, P., additional, Lacroix, L., additional, Mackay, A., additional, Jones, C., additional, Puget, S., additional, Sainte-Rose, C., additional, Blauwblomme, T., additional, Varlet, P., additional, Entz-Werle, N., additional, Maugard, C., additional, Bougeard, G., additional, Nguyen, A., additional, Chenard, M. P., additional, Schneider, A., additional, Gaub, M. P., additional, Tsoli, M., additional, Vanniasinghe, A., additional, Luk, P., additional, Dilda, P., additional, Haber, M., additional, Hogg, P., additional, Ziegler, D., additional, Simon, S., additional, Monje, M., additional, Gurova, K., additional, Gudkov, A., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Zamecnik, J., additional, Kyncl, M., additional, Tichy, M., additional, Puchmajerova, A., additional, Stary, J., additional, Sumerauer, D., additional, Boult, J., additional, Vinci, M., additional, Perryman, L., additional, Box, G., additional, Jury, A., additional, Popov, S., additional, Ingram, W., additional, Eccles, S., additional, Robinson, S., additional, Emir, S., additional, Demir, H. A., additional, Bayram, C., additional, Cetindag, F., additional, Kabacam, G. B., additional, Fettah, A., additional, Li, J., additional, Jamin, Y., additional, Cummings, C., additional, Bamber, J., additional, Sinkus, R., additional, Nandhabalan, M., additional, Bjerke, L., additional, Burford, A., additional, von Bueren, A., additional, Baudis, M., additional, Clarke, P., additional, Collins, I., additional, Workman, P., additional, Olaciregui, N., additional, Mora, J., additional, Carcaboso, A., additional, Bullock, A., additional, Alonso, M., additional, de Torres, C., additional, Cruz, O., additional, Pencreach, E., additional, Moussalieh, F. M., additional, Guenot, D., additional, Namer, I., additional, Pollack, I., additional, Jakacki, R., additional, Butterfield, L., additional, Hamilton, R., additional, Panigrahy, A., additional, Potter, D., additional, Connelly, A., additional, Dibridge, S., additional, Whiteside, T., additional, Okada, H., additional, Ahsan, S., additional, Raabe, E., additional, Haffner, M., additional, Warren, K., additional, Quezado, M., additional, Ballester, L., additional, Eberhart, C., additional, Rodriguez, F., additional, Ramachandran, C., additional, Nair, S., additional, Quirrin, K.-W., additional, Khatib, Z., additional, Escalon, E., additional, Melnick, S., additional, Classen, C. F., additional, Hofmann, M., additional, Schmid, I., additional, Simon, T., additional, Maass, E., additional, Russo, A., additional, Fleischhack, G., additional, Becker, M., additional, Hauch, H., additional, Sander, A., additional, Grasso, C., additional, Berlow, N., additional, Liu, L., additional, Davis, L., additional, Huang, E., additional, Woo, P., additional, Tang, Y., additional, Ponnuswami, A., additional, Chen, S., additional, Huang, Y., additional, Hutt-Cabezas, M., additional, Dret, L., additional, Meltzer, P., additional, Mao, H., additional, Abraham, J., additional, Fouladi, M., additional, Svalina, M. N., additional, Wang, N., additional, Hulleman, E., additional, Li, X.-N., additional, Keller, C., additional, Spellman, P. T., additional, Pal, R., additional, Jansen, M. H. A., additional, Sewing, A. C. P., additional, Lagerweij, T., additional, Vuchts, D. J., additional, van Vuurden, D. G., additional, Caretti, V., additional, Wesseling, P., additional, Kaspers, G. J. L., additional, Cohen, K., additional, Pearl, M., additional, Kogiso, M., additional, Zhang, L., additional, Qi, L., additional, Lindsay, H., additional, Lin, F., additional, Berg, S., additional, Muscal, J., additional, Amayiri, N., additional, Tabori, U., additional, Campbel, B., additional, Bakry, D., additional, Aronson, M., additional, Durno, C., additional, Gallinger, S., additional, Malkin, D., additional, Qaddumi, I., additional, Musharbash, A., additional, Swaidan, M., additional, Al-Hussaini, M., additional, Shandilya, S., additional, McCully, C., additional, Murphy, R., additional, Akshintala, S., additional, Cole, D., additional, Macallister, R. P., additional, Cruz, R., additional, Widemann, B., additional, Salloum, R., additional, Smith, A., additional, Glaunert, M., additional, Ramkissoon, A., additional, Peterson, S., additional, Baker, S., additional, Chow, L., additional, Sandgren, J., additional, Pfeifer, S., additional, Popova, S., additional, Alafuzoff, I., additional, de Stahl, T. D., additional, Pietschmann, S., additional, Kerber, M. J., additional, Zwiener, I., additional, Henke, G., additional, Muller, K., additional, Sieow, N. Y.-F., additional, Hoe, R. H. M., additional, Tan, A. M., additional, Chan, M. Y., additional, Soh, S. Y., additional, Burrell, K., additional, Chornenkyy, Y., additional, Remke, M., additional, Golbourn, B., additional, Barzczyk, M., additional, Taylor, M., additional, Rutka, J., additional, Dirks, P., additional, Zadeh, G., additional, Agnihotri, S., additional, Hashizume, R., additional, Ihara, Y., additional, Andor, N., additional, Chen, X., additional, Lerner, R., additional, Huang, X., additional, Tom, M., additional, Solomon, D., additional, Mueller, S., additional, Petritsch, C., additional, Zhang, Z., additional, Gupta, N., additional, Waldman, T., additional, Dujua, A., additional, Co, J., additional, Hernandez, F., additional, Doromal, D., additional, Hegde, M., additional, Wakefield, A., additional, Brawley, V., additional, Grada, Z., additional, Byrd, T., additional, Chow, K., additional, Krebs, S., additional, Heslop, H., additional, Gottschalk, S., additional, Yvon, E., additional, Ahmed, N., additional, Cornilleau, G., additional, Paulsson, J., additional, Andreiuolo, F., additional, Guerrini-Rousseau, L., additional, Geoerger, B., additional, Vassal, G., additional, Ostman, A., additional, Parsons, D. W., additional, Trevino, L. R., additional, Gao, F., additional, Shen, X., additional, Hampton, O., additional, Kosigo, M., additional, Baxter, P. A., additional, Su, J. M., additional, Chintagumpala, M., additional, Dauser, R., additional, Adesina, A., additional, Plon, S. E., additional, Wheeler, D. A., additional, Lau, C. C., additional, Gielen, G., additional, Muehlen, A. z., additional, Kwiecien, R., additional, Wolff, J., additional, Lulla, R. R., additional, Laskowski, J., additional, Goldman, S., additional, Gopalakrishnan, V., additional, Fangusaro, J., additional, Kieran, M., additional, Fontebasso, A., additional, Papillon-Cavanagh, S., additional, Schwartzentruber, J., additional, Nikbakht, H., additional, Gerges, N., additional, Fiset, P.-O., additional, Bechet, D., additional, Faury, D., additional, De Jay, N., additional, Ramkissoon, L., additional, Corcoran, A., additional, Jones, D., additional, Sturm, D., additional, Johann, P., additional, Tomita, T., additional, Nagib, M., additional, Bendel, A., additional, Goumnerova, L., additional, Bowers, D. C., additional, Leonard, J. R., additional, Rubin, J. B., additional, Alden, T., additional, DiPatri, A., additional, Browd, S., additional, Leary, S., additional, Jallo, G., additional, Prados, M. D., additional, Banerjee, A., additional, Carret, A.-S., additional, Ellezam, B., additional, Crevier, L., additional, Klekner, A., additional, Bognar, L., additional, Hauser, P., additional, Garami, M., additional, Myseros, J., additional, Dong, Z., additional, Siegel, P. M., additional, Gump, W., additional, Ayyanar, K., additional, Ragheb, J., additional, Krieger, M., additional, Kiehna, E., additional, Robison, N., additional, Harter, D., additional, Gardner, S., additional, Handler, M., additional, Foreman, N., additional, Brahma, B., additional, MacDonald, T., additional, Malkin, H., additional, Chi, S., additional, Manley, P., additional, Bandopadhayay, P., additional, Greenspan, L., additional, Ligon, A., additional, Albrecht, S., additional, Ligon, K. L., additional, Majewski, J., additional, Jabado, N., additional, Cordero, F., additional, Halvorson, K., additional, Taylor, I., additional, Hutt, M., additional, Weingart, M., additional, Price, A., additional, Kantar, M., additional, Onen, S., additional, Kamer, S., additional, Turhan, T., additional, Kitis, O., additional, Ertan, Y., additional, Cetingul, N., additional, Anacak, Y., additional, Akalin, T., additional, Ersahin, Y., additional, Mason, G., additional, Ho, C., additional, Crozier, F., additional, Vezina, G., additional, Packer, R., additional, Hwang, E., additional, Gilheeney, S., additional, Millard, N., additional, DeBraganca, K., additional, Khakoo, Y., additional, Kramer, K., additional, Wolden, S., additional, Donzelli, M., additional, Fischer, C., additional, Petriccione, M., additional, Dunkel, I., additional, Afzal, S., additional, Fleming, A., additional, Larouche, V., additional, Zelcer, S., additional, Johnston, D. L., additional, Kostova, M., additional, Mpofu, C., additional, Decarie, J.-C., additional, Strother, D., additional, Lafay-Cousin, L., additional, Eisenstat, D., additional, Fryer, C., additional, Hukin, J., additional, Hsu, M., additional, Lasky, J., additional, Moore, T., additional, Liau, L., additional, Davidson, T., additional, Prins, R., additional, Hassal, T., additional, Baugh, J., additional, Kirkendall, J., additional, Doughman, R., additional, Leach, J., additional, Jones, B., additional, Miles, L., additional, Hargrave, D., additional, Jacques, T., additional, Savage, S., additional, Saunders, D., additional, Wallace, R., additional, Flutter, B., additional, Morgenestern, D., additional, Blanco, E., additional, Howe, K., additional, Lowdell, M., additional, Samuel, E., additional, Michalski, A., additional, Anderson, J., additional, Arakawa, Y., additional, Umeda, K., additional, Watanabe, K.-i., additional, Mizowaki, T., additional, Hiraoka, M., additional, Hiramatsu, H., additional, Adachi, S., additional, Kunieda, T., additional, Takagi, Y., additional, Miyamoto, S., additional, Venneti, S., additional, Santi, M., additional, Felicella, M. M., additional, Sullivan, L. M., additional, Dolgalev, I., additional, Martinez, D., additional, Perry, A., additional, Lewis, P. W., additional, Allis, D. C., additional, Thompson, C. B., additional, and Judkins, A. R., additional
Published: 2014
Full Text: View/download PDF

12. ATYPICAL TERATOID RHABDOID TUMOUR

Author: Bertozzi, A. I., primary, Munzer, C., additional, Fouyssac, F., additional, Andre, N., additional, Boetto, S., additional, Leblond, P., additional, Bourdeaut, F., additional, Dufour, C., additional, Deshpande, R. K., additional, Bhat, K. G., additional, Mahalingam, S., additional, Muscat, A., additional, Cain, J., additional, Ferguson, M., additional, Popovski, D., additional, Algar, E., additional, Rossello, F. J., additional, Jayasekara, S., additional, Watkins, D. N., additional, Hodge, J., additional, Ashley, D., additional, Hishii, M., additional, Saito, M., additional, Arai, H., additional, Han, Z. Y., additional, Richer, W., additional, Lucchesi, C., additional, Freneaux, P., additional, Nicolas, A., additional, Grison, C., additional, Pierron, G., additional, Delattre, O., additional, Epari, S., additional, TS, N., additional, Gupta, T., additional, Chinnaswamy, G., additional, Sastri, J. G., additional, Shetty, P., additional, Moiyadi, A., additional, Jalali, R., additional, Fay-McClymont, T., additional, Johnston, D., additional, Janzen, L., additional, Guger, S., additional, Scheinemann, K., additional, Fleming, A., additional, Fryer, C., additional, Hukin, J., additional, Mabbott, D., additional, Huang, A., additional, Bouffet, E., additional, Lafay-Cousin, L., additional, Kawamura, A., additional, Yamamoto, K., additional, Nagashima, T., additional, Bartelheim, K., additional, Benesch, M., additional, Buchner, J., additional, Gerss, J., additional, Hasselblatt, M., additional, Kortmann, R.-D., additional, Fleischack, G., additional, Quiroga, E., additional, Reinhard, H., additional, Schneppenheim, R., additional, Seeringer, A., additional, Siebert, R., additional, Timmermann, B., additional, Warmuth-Metz, M., additional, Schmid, I., additional, Fruhwald, M. C., additional, Kerl, K., additional, Klingebiel, T., additional, Al-Kofide, A., additional, Khafaga, Y., additional, Al-Hindi, H., additional, Dababo, M., additional, Ul-Haq, A., additional, Anas, M., additional, Barria, M. G., additional, Siddiqui, K., additional, Hassounah, M., additional, Ayas, M., additional, Al-Shail, E., additional, Jeibmann, A., additional, Eikmeier, K., additional, Linge, A., additional, Johann, P., additional, Koos, B., additional, Kool, M., additional, Pfister, S. M., additional, Paulus, W., additional, Schuller, U., additional, Junckerstorff, R., additional, Rosenblum, M. K., additional, Alassiri, A. H., additional, Rossi, S., additional, Gottardo, N., additional, Toledano, H., additional, Viscardi, E., additional, Witkowski, L., additional, Nagel, I., additional, Oyen, F., additional, Foulkes, W. D., additional, Schrey, D., additional, Malietzis, G., additional, Chi, S., additional, Marshall, L., additional, Carceller, F., additional, Moreno, L., additional, Zacharoulis, S., additional, Bhardwaj, R., additional, Chakravadhanula, M., additional, Ozals, V., additional, Hampton, C., additional, Metpally, R., additional, Grillner, P., additional, Asmundsson, J., additional, Gustavsson, B., additional, Holm, S., additional, Johann, P. D., additional, Korshunov, A., additional, Ryzhova, M., additional, Milde, T., additional, Witt, O., additional, Jones, D. T. W., additional, Hovestadt, V., additional, Gajjar, A., additional, Fruhwald, M., additional, Pfister, S., additional, Finetti, M., additional, Pons, A. d. C., additional, Selby, M., additional, Smith, A., additional, Crosier, S., additional, Wood, J., additional, Skalkoyannis, B., additional, Bailey, S., additional, Clifford, S., additional, Williamson, D., additional, Rutkowski, S., additional, Kortmann, R. D., additional, Graf, N., additional, Boos, J., additional, Nysom, K., additional, Moreno, N., additional, Holsten, T., additional, Ahlfeld, J., additional, Mertins, J., additional, Hotfilder, M., additional, Schleicher, S., additional, Handgretinger, R., additional, Meisterernst, M., additional, Schmidt, C., additional, Dittmar, S., additional, Chan, G. C. F., additional, Shing, M. M. K., additional, Yuen, H. L., additional, Li, R. C. H., additional, Ling, S. L., additional, Slavc, I., additional, Peyrl, A., additional, Chocholous, M., additional, Azizi, A., additional, Czech, T., additional, Dieckmann, K., additional, Haberler, C., additional, Leiss, U., additional, Gotti, G., additional, Biassoni, V., additional, Schiavello, E., additional, Spreafico, F., additional, Pecori, E., additional, Gandola, L., additional, Massimino, M., additional, Kornelius, K., additional, Yano, H., additional, Nakayama, N., additional, Ohe, N., additional, Ozeki, M., additional, Kanda, K., additional, Kimura, T., additional, Hori, T., additional, Fukao, T., additional, Iwama, T., additional, Weil, A. G., additional, Diaz, A., additional, Gernsback, J., additional, Bhatia, S., additional, Ragheb, J., additional, Niazi, T., additional, Khatib, Z., additional, Zoghbi, A., additional, Meisterernst, a. M., additional, Birks, D., additional, Griesinger, A., additional, Amani, V., additional, Donson, A., additional, Posner, R., additional, Dunham, C., additional, Kleinschmidt-DeMasters, B. K., additional, Handler, M., additional, Vibhakar, R., additional, Foreman, N., additional, Zhou, L., additional, Catchpoole, D., additional, Kakkar, A., additional, Biswas, A., additional, Suri, V., additional, Sharma, M., additional, Kale, S., additional, Mahapatra, A., additional, Sarkar, C., additional, Torchia, J., additional, Picard, D., additional, Ho, K. C., additional, Khuong-Quang, D.-A., additional, Louterneau, L., additional, Bourgey, M., additional, Chan, T., additional, Golbourn, B., additional, Cousin, L.-L., additional, Taylor, M. D., additional, Dirks, P., additional, Rutka, J. T., additional, Hawkins, C., additional, Majewski, J., additional, Kim, S.-K., additional, Jabado, N., additional, Chang, J. H.-C., additional, Confer, M., additional, Chang, A., additional, Goldman, S., additional, Dunn, M., additional, and Hartsell, W., additional
Published: 2014
Full Text: View/download PDF

13. EPENDYMOMA

Author: Zaghloul, M., primary, Elbeltagy, M., additional, Mousa, A., additional, Eldebawy, E., additional, Amin, A., additional, Pavelka, Z., additional, Vranova, V., additional, Valaskova, I., additional, Tomasikova, L., additional, Oltova, A., additional, Ventruba, J., additional, Mackerle, Z., additional, Kren, L., additional, Skotakova, J., additional, Zitterbart, K., additional, Sterba, J., additional, Milde, T., additional, Kleber, S., additional, Korshunov, A., additional, Witt, H., additional, Hielscher, T., additional, Koch, P., additional, Koch, H.-G., additional, Jugold, M., additional, Deubzer, H. E., additional, Oehme, I., additional, Lodrini, M., additional, Grone, H.-J., additional, Benner, A., additional, Brustle, O., additional, Gilbertson, R. J., additional, von Deimling, A., additional, Kulozik, A. E., additional, Pfister, S. M., additional, Ana, M.-V., additional, Witt, O., additional, Kool, M., additional, Mack, S. C., additional, Taylor, M. D., additional, Fouyssac, F., additional, Schmitt, E., additional, Mansuy, L., additional, Marchal, J.-C., additional, Coffinet, L., additional, Bernier, V., additional, Chastagner, P., additional, Sperl, D., additional, Zacharoulis, S., additional, Massimino, M., additional, Schiavello, E., additional, Pizer, B., additional, Piette, C., additional, Kitanovski, L., additional, von Hoff, K., additional, Quehenberger, F., additional, Rutkowski, S., additional, Benesch, M., additional, Tzaridis, T.-D., additional, Bender, S., additional, Pfaff, E., additional, Barbus, S., additional, Bageritz, J., additional, Jones, D.-T.-W., additional, Kulozik, A., additional, Lichter, P., additional, Pfister, S.-M., additional, Song, S.-H., additional, Kang, C.-W., additional, Kim, S.-H., additional, Bandopadhayay, P., additional, Ullrich, N., additional, Goumnerova, L., additional, Scott, R. M., additional, Silvera, V. M., additional, Ligon, K. L., additional, Marcus, K. J., additional, Robison, N., additional, Manley, P. E., additional, Chi, S., additional, Kieran, M. W., additional, Biassoni, V., additional, Pierani, P., additional, Cesaro, S., additional, Maura, M., additional, Mack, S., additional, Jager, N., additional, Jones, D. T. W., additional, Stutz, A., additional, Northcott, P. A., additional, Fults, D. W., additional, Gupta, N., additional, Karajannis, M., additional, Rutka, J. T., additional, Korbel, J., additional, de Rezende, A. C. P., additional, Chen, M. J., additional, da Silva, N. S., additional, Cappellano, A., additional, Cavalheiro, S., additional, Weltman, E., additional, Currle, S., additional, Thiruvenkatam, R., additional, Murugesan, M., additional, Kranenburg, T., additional, Phoenix, T., additional, Gupta, K., additional, Gilbertson, R., additional, Rogers, H., additional, Kilday, J.-P., additional, Mayne, C., additional, Ward, J., additional, Adamowicz-Brice, M., additional, Schwalbe, E., additional, Clifford, S., additional, Coyle, B., additional, Grundy, R., additional, Mitra, B., additional, Domerg, C., additional, Andreiuolo, F., additional, Osteso-Ibanez, T., additional, Mauguen, A., additional, Varlet, P., additional, Le Deley, M.-C., additional, Lowe, J., additional, Ellison, D. W., additional, Grill, J., additional, Grundy, R. G., additional, Fleischhack, G., additional, Pajtler, K., additional, Zimmermann, M., additional, Warmuth-Metz, M., additional, Kortmann, R.-D., additional, Pietsch, T., additional, Faldum, A., additional, Bode, U., additional, Gandola, L., additional, Pecori, E., additional, Scarzello, G., additional, Barra, S., additional, Mascarin, M., additional, Scoccianti, S., additional, Mussano, A., additional, Garre, M. L., additional, Jacopo, S., additional, Viscardi, E., additional, Balter, R., additional, Bertin, D., additional, Giangaspero, F., additional, Pearlman, M., additional, Khatua, S., additional, Van Meter, T., additional, Koul, D., additional, Yung, A., additional, Paulino, A., additional, Su, J., additional, Dauser, R., additional, Whitehead, W., additional, Teh, B., additional, Chintagumpala, M., additional, Perek, D., additional, Drogosiewicz, M., additional, Filipek, I., additional, Polnik, M. P., additional, Baginska, B. D., additional, Wachowiak, J., additional, Kazmierczak, B., additional, Sobol, G., additional, Musiol, K., additional, Kowalczyk, J., additional, Slusarz, H. W., additional, Peregud-Pogorzelski, J., additional, Grajkowska, W., additional, Roszkowski, M., additional, Teo, W.-Y., additional, Okcu, F., additional, Mahajan, A., additional, Adesina, A., additional, Jea, A., additional, Bollo, R., additional, Paulino, A. C., additional, Velez-Char, N., additional, Doerner, E., additional, Muehlen, A. z., additional, Vladimirova, V., additional, Kortmann, R., additional, Friedrich, C., additional, von Bueren, A. O., additional, Barszczyk, M., additional, Buczkowicz, P., additional, Morrison, A., additional, Tabori, U., additional, Hawkins, C., additional, Krajewski, K., additional, Kammler, G., additional, von Bueren, A., additional, Krauss, J., additional, Ferreira, C., additional, Dieffenbach, G., additional, Barbosa, C., additional, Cuny, P., additional, Piccinin, E., additional, Brenca, M., additional, Lorenzetto, E., additional, Sardi, I., additional, Genitori, L., additional, Pollo, B., additional, Maestro, R., additional, Modena, P., additional, MacDonald, S., additional, Ebb, D., additional, Lavally, B., additional, Yeap, B., additional, Marcus, K., additional, Tarbell, N., additional, Yock, T., additional, Schittone, S., additional, Donson, A., additional, Birks, D., additional, Amani, V., additional, Griesinger, A., additional, Handler, M., additional, Madey, M., additional, Merchant, T., additional, Foreman, N., additional, Hukin, J., additional, Ailon, T., additional, Dunham, C., additional, Carret, A.-S., additional, McNeely, P. D., additional, Zelcer, S., additional, Wilson, B., additional, Lafay-Cousin, L., additional, Johnston, D., additional, Eisenstat, D., additional, Silva, M., additional, Jabado, N., additional, Yip, S., additional, Goddard, K., additional, Fryer, C., additional, Hendson, G., additional, Dunn, S., additional, Singhal, A., additional, Lassen-Ramshad, Y., additional, Vestergaard, A., additional, Seiersen, K., additional, Schultz, H. P., additional, Hoeyer, M., additional, Petersen, J. B., additional, Moreno, L., additional, Popov, S., additional, Jury, A., additional, Al Sarraj, S., additional, Jones, C., additional, Bowers, D., additional, Gargan, L., additional, Horton, C. J., additional, Rakheja, D., additional, Margraf, L., additional, Yeung, J., additional, Hamilton, R., additional, Okada, H., additional, Jakacki, R., additional, Pollack, I., additional, Fleming, A., additional, Saint-Martin, C., additional, Freeman, C., additional, Albrecht, S., additional, and Montes, J.-L., additional
Published: 2012
Full Text: View/download PDF

14. DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Author: Zaghloul, M., primary, Ahmed, S., additional, Eldebaway, E., additional, Mousa, A., additional, Amin, A., additional, Elkhateeb, N., additional, Sabry, M., additional, Ogiwara, H., additional, Morota, N., additional, Sufit, A., additional, Donson, A., additional, Birks, D., additional, Patel, P., additional, Foreman, N., additional, Handler, M., additional, Massimino, M., additional, Biassoni, V., additional, Gandola, L., additional, Schiavello, E., additional, Pecori, E., additional, Potepan, P., additional, Bach, F., additional, Janssens, G. O., additional, Jansen, M. H., additional, Lauwers, S. J., additional, Nowak, P. J., additional, Oldenburger, F. R., additional, Bouffet, E., additional, Saran, F., additional, van Ulzen, K. K., additional, van Lindert, E. J., additional, Schieving, J. H., additional, Boterberg, T., additional, Kaspers, G. J., additional, Span, P. N., additional, Kaanders, J. H., additional, Gidding, C. E., additional, Hargrave, D., additional, Bailey, S., additional, Howman, A., additional, Pizer, B., additional, Harris, D., additional, Jones, D., additional, Kearns, P., additional, Picton, S., additional, Wheatley, K., additional, Gibson, M., additional, Glaser, A., additional, Connolly, D., additional, Kawamura, A., additional, Nagashima, T., additional, Yamamoto, K., additional, Sakata, J., additional, Lober, R., additional, Freret, M., additional, Fisher, P., additional, Edwards, M., additional, Yeom, K., additional, Monje, M., additional, Jansen, M., additional, Aliaga, E. S., additional, Van Der Hoeven, E., additional, Van Vuurden, D., additional, Heymans, M., additional, Gidding, C., additional, De Bont, E., additional, Reddingius, R., additional, Peeters-Scholte, C., additional, van Meeteren, A. S., additional, Gooskens, R., additional, Granzen, B., additional, Paardekoper, G., additional, Janssens, G., additional, Noske, D., additional, Barkhof, F., additional, Vandertop, W. P., additional, Kaspers, G., additional, Saratsis, A., additional, Yadavilli, S., additional, Nazarian, J., additional, Mitra, S., additional, Mallick, S., additional, Kim, J., additional, Beachy, P., additional, Nobre, L., additional, Vasconcelos, F., additional, Lima, F., additional, Mattos, D., additional, Kuiven, N., additional, Lima, G., additional, Silveira, J., additional, Sevilha, M., additional, Lima, M. A., additional, Ferman, S., additional, Leblond, P., additional, Lansiaux, A., additional, Rialland, X., additional, Gentet, J.-C., additional, Geoerger, B., additional, Frappaz, D., additional, Aerts, I., additional, Bernier-Chastagner, V., additional, Shah, R., additional, Zaky, W., additional, Grimm, J., additional, Bluml, S., additional, Wong, K., additional, Dhall, G., additional, Caretti, V., additional, Schellen, P., additional, Lagerweij, T., additional, Bugiani, M., additional, Navis, A., additional, Wesseling, P., additional, Noske, D. P., additional, Wurdinger, T., additional, Lee, H., additional, Ziegler, D., additional, Schroeder, K., additional, Huang, E., additional, Berlow, N., additional, Patel, R., additional, Becher, O., additional, Taylor, I., additional, Mao, X.-g., additional, Hutt, M., additional, Weingart, M., additional, Kahlert, U., additional, Maciacyk, J., additional, Nikkhah, G., additional, Eberhart, C., additional, Raabe, E., additional, Barton, K., additional, Misuraca, K., additional, Zhou, Z., additional, Rotman, L., additional, Ho, S., additional, Souweidane, M., additional, Lim, K. J., additional, Warren, K., additional, Chang, H., additional, Lightner, D., additional, Haque, S., additional, Khakoo, Y., additional, Dunkel, I., additional, Gilheeney, S., additional, Kramer, K., additional, Lyden, D., additional, Wolden, S., additional, Greenfield, J., additional, De Braganca, K., additional, Ting-Rong, H., additional, Muh-Li, L., additional, Kai-Ping, C., additional, Tai-Tong, W., additional, Hsin-Hung, C., additional, Kebudi, R., additional, Cakir, F. B., additional, Agaoglu, F. Y., additional, Gorgun, O., additional, Dizdar, Y., additional, Ayan, I., additional, Darendeliler, E., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Kodet, R., additional, Kyncl, M., additional, Tichy, M., additional, Stary, J., additional, Sumerauer, D., additional, Minturn, J., additional, Shu, H.-K., additional, Fisher, M., additional, Patti, R., additional, Janss, A., additional, Allen, J., additional, Phillips, P., additional, Belasco, J., additional, Taylor, K., additional, Baudis, M., additional, von Beuren, A., additional, Fouladi, M., additional, and Jones, C., additional
Published: 2012
Full Text: View/download PDF

15. Pediatrics Clinical Research

Author: Wrede, B., primary, Peters, O., additional, Kordes, U., additional, Kutluk, T., additional, Hasselblatt, M., additional, Rytting, M., additional, Rutkowski, S., additional, Mahajan, A., additional, Pietsch, T., additional, Thall, P., additional, Wolff, J. E., additional, Pfister, S., additional, Bingham, R., additional, Vats, T., additional, Rokes, C., additional, Brown, R., additional, Creach, K. M., additional, Rubin, J. B., additional, Leonard, J. R., additional, Limbrick, D. D., additional, Smyth, M. D., additional, Dacey, R. G., additional, Rich, K. M., additional, Dowling, J. L., additional, Linette, G. P., additional, King, A. A., additional, Michalski, J. M., additional, Simpson, J. R., additional, Park, T. S., additional, Perry, A., additional, Mansur, D. B., additional, Gururangan, S., additional, Panandikar, A. P., additional, Broniscer, A., additional, Huang, A., additional, Kellie, S., additional, Ellison, D., additional, Gajjar, A., additional, Aguilera, D., additional, Goldman, S., additional, Tomita, T., additional, Fangusaro, J., additional, Poussaint, T. Y., additional, Onar, A., additional, Gilbertson, R., additional, Packer, R., additional, McClendon, R., additional, Friedman, H., additional, Boyett, J., additional, Baker, J. N., additional, Tagen, M., additional, Onar-Thomas, A., additional, Gilbertson, R. J., additional, Davidoff, A. M., additional, Pai-Panandiker, A., additional, Leung, W., additional, Chin, T. K., additional, Stewart, C. F., additional, Kocak, M., additional, Rowland, C., additional, Merchant, T. E., additional, Kaste, S., additional, Allen, J., additional, Donahue, B., additional, Mathew, J., additional, Kretschmar, C., additional, Pollack, I., additional, Jakacki, R., additional, Massimino, M., additional, Biassoni, V., additional, Gandola, L., additional, Ferroli, P., additional, Bongarzone, I., additional, Spreafico, F., additional, Pecori, E., additional, Schiavello, E., additional, Modena, P., additional, Bach, F., additional, Potepan, P., additional, Slavc, I., additional, Peyrl, A., additional, Czech, T., additional, Haberler, C., additional, Dieckmann, K., additional, Brown, R. J., additional, Dhall, G., additional, Marachelian, A., additional, Gozali, A., additional, Butturini, A., additional, Gilles, F., additional, Thompson, S. J., additional, Gardner, S., additional, Finlay, J. L., additional, Eisenstat, D. D., additional, and Evans, A., additional
Published: 2010
Full Text: View/download PDF

16. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma

Author: Carlo Giussani, Paola Peretta, Daniele Bertin, Piergiorgio Modena, E. Schiavello, Maura Massimino, Ermanno Giombelli, Laura Valentini, Rosalba Miceli, Maria Luisa Garrè, Luna Boschetti, P Bertolini, Giuseppina Calareso, Lorenza Gandola, Salvina Barra, Paolo Ferroli, Barbara Diletto, Giuseppe Cinalli, Veronica Biassoni, Annamaria Buccoliero, Felice Giangaspero, Lucia Quaglietta, Maurizio Mascarin, Angela Mastronuzzi, Milena La Spina, Elisabetta Viscardi, Carlo Efisio Marras, Anna Mussano, Giovanni Scarzello, Armando Cama, Emilia Pecori, Bianca Pollo, Iacopo Sardi, Rita Balter, Francesca R. Buttarelli, Manila Antonelli, Silvia Scoccianti, Lorenzo Genitori, Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, and Gandola, L
Subjects: Male, Ependymoma, Cancer Research, medicine.medical_treatment, Kaplan-Meier Estimate, Neurosurgical Procedures, surgery, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Child, Prospective cohort study, Adjuvant, Etoposide, grade, Brain Neoplasms, boost, ependymoma, prognosis, Chemoradiotherapy, Chemotherapy regimen, Treatment Outcome, Oncology, Vincristine, Child, Preschool, 030220 oncology & carcinogenesis, Female, prognosi, medicine.drug, medicine.medical_specialty, Adolescent, Cyclophosphamide, Disease-Free Survival, 03 medical and health sciences, medicine, Humans, Clinical Investigation, Progression-free survival, Preschool, Radiotherapy, business.industry, Infant, Chemoradiotherapy, Adjuvant, medicine.disease, Surgery, Radiation therapy, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract: Background This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). Methods WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. Results From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. Conclusions In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.
Published: 2016

17. Regression of ovarian enlargement in pharmacological ovulation induction

Author: G. Pierno, E. Pecori, F. M. Severi, L. Stradella, Luigi Cobellis, E. De Lucia, Felice Petraglia, Cobellis, Luigi, Pecori, E, DE LUCIA, E, Pierno, G, Stradella, L, Severi, Fm, and Petraglia, F.
Subjects: Adult, OHSS, Ovarian Regression, Ovulation Induction, Pharmacological, medicine.medical_specialty, Time Factors, Endocrinology, Diabetes and Metabolism, media_common.quotation_subject, medicine.medical_treatment, Ovarian hyperstimulation syndrome, Physiology, Fertilization in Vitro, Group B, Ovarian Hyperstimulation Syndrome, Endocrinology, Obstetrics and gynaecology, Humans, Medicine, Ovulation, Ultrasonography, media_common, Gynecology, In vitro fertilisation, Estradiol, business.industry, Incidence (epidemiology), Ovary, Obstetrics and Gynecology, medicine.disease, Polycystic ovary, Infertility, Female, Ovulation induction, business, Polycystic Ovary Syndrome
Abstract: The aim of the present study was to determine a possible relationship between ovarian functionality and regression of ovarian enlargement according to the different categories and degree of severity of ovarian hyperstimulation syndrome (OHSS). Among a group of sterile woman (n = 111), two subgroups were studied: group A (n = 15), patients affected by severe syndrome; and group B (n = 96), patients with massive ovarian enlargement only. The protocol of ovarian stimulation was conducted in various in vitro fertilization (IVF) centers; ultrasonographic examination and hematological checks were carried out daily; patients with severe OHSS were hospitalized. In women of group A, severe symptoms disappeared in 7-11 days; in nine patients with regular cycles ovary size returned to normal in about 30-40 days, whereas in six subjects with anovulatory cycles, the resolution was recorded in about 50-60 days; serum estradiol returned to physiological levels within 20-30 days. Women of group B showed a spontaneous regression at different times: in 43 subjects that presented regular ovulatory cycles, the resolution was recorded in about 30-40 days, whereas in 36 women with anovulatory cycles before pharmacological induction, resolution occurred in 50-60 days, and in 17 cases with polycystic ovary syndrome before pharmacological ovulation, an incomplete resolution was obtained; serum estradiol levels returned to a physiological range within 20-30 days. Our results show that in patients with regular ovulatory cycles, resolution of symptoms is obtained in a shorter time than in patients with anovulatory cycles before pharmacological induction.
Published: 2001

18. Dosimetric Comparison Between Proton and Photon Radiation Therapies for Pediatric Neuroblastoma.

Author: Mirandola A, Colombo F, Cavagnetto F, Cavallo A, Gusinu M, Molinelli S, Pignoli E, Ciocca M, Barra S, Giannelli F, Pecori E, Jereczek-Fossa BA, Orlandi E, and Vennarini S
Abstract: Purpose: The aim of this study is to determine the most beneficial radiation treatment technique for pediatric patients with thoracic and abdominal neuroblastoma (NBL), through a dosimetric comparison between photon Volumetric Modulated Arc Therapy and proton Intensity-Modulated Proton Therapy treatment plans., Materials and Methods: A retrospective analysis was conducted on a multicentre case series of 19 patients with thoracic and/or abdominal NBL who underwent radiation therapy, following the recommendations of the European protocol for high-risk NBL (HR-NBL2/SIOPEN). The prescribed dose was 21.6 Gy in 12 fractions (1.8 Gy/fraction) delivered over the preoperative disease volume. The dose volume histograms were analyzed for each patient, and a Wilcoxon signed-rank test with a significance level of 0.01 was employed to assess statistical differences between the dosimetric parameters investigated. Two homogeneity indices (HI and new HI) were compared to evaluate the uniformity in dose, delivered to the adjacent vertebrae (VBs_Adj)., Results: Both radiation techniques conform to the protocol regarding CTV/PTV coverage for every location. Proton therapy resulted in statistically significant dose sparing for the heart and lungs in supradiaphragmatic locations and for the contralateral kidney, liver, spleen, and bowel in subdiaphragmatic locations. For both techniques, sparing the non-adjacent vertebrae (VBs_NAdj) results more challenging, although promising results were obtained. Furthermore, the dose delivered to the VBs_Adj was not statistically different, in terms of homogeneity, for the 2 radiation techniques that both met the protocol's requirements., Conclusion: This dosimetric analysis highlights the potential of protons to reduce radiation dose to healthy tissue. These findings apply to all the investigated patients, regardless of primary tumor location, making proton therapy a valuable option for the treatment of neuroblastoma. However, a multidisciplinary assessment of each case is essential to ensure the selection of the most effective and suitable treatment modality., Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Alfredo Mirandola reports administrative support, article publishing charges, equipment, drugs, or supplies, statistical analysis, travel, and writing assistance were provided by National Centre of Oncological Hadrontherapy. Alfredo Mirandola reports a relationship with the National Centre of Oncological Hadrontherapy that includes: employment. Alfredo Mirandola has patent issued to no. Nothing to add If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)
Published: 2024
Full Text: View/download PDF

19. Proton Therapy in Non-Rhabdomyosarcoma Soft Tissue Sarcomas of Children and Adolescents.

Author: Vennarini S, Colombo F, Mirandola A, Orlandi E, Pecori E, Chiaravalli S, Massimino M, Casanova M, and Ferrari A
Abstract: This paper provides insights into the use of Proton Beam Therapy (PBT) in pediatric patients with non-rhabdomyosarcoma soft tissue sarcomas (NRSTS). NRSTS are a heterogeneous group of rare and aggressive mesenchymal extraskeletal tumors, presenting complex and challenging clinical management scenarios. The overall survival rate for patients with NRSTS is around 70%, but the outcome is strictly related to the presence of various variables, such as the histological subtype, grade of malignancy and tumor stage at diagnosis. Multimodal therapy is typically considered the preferred treatment for high-grade NRSTS. Radiotherapy plays a key role in the treatment of children and adolescents with NRSTS. However, the potential for radiation-induced side effects partially limits its use. Therefore, PBT represents a very suitable therapeutic option for these patients. The unique depth-dose characteristics of protons can be leveraged to minimize doses to healthy tissue significantly, potentially allowing for increased tumor doses and enhanced preservation of surrounding tissues. These benefits suggest that PBT may improve local control while reducing toxicity and improving quality of life. While clear evidence of therapeutic superiority of PBT over other modern photon techniques in NRSTS is still lacking-partly due to the limited data available-PBT can be an excellent treatment option for young patients with these tumors. A dedicated international comprehensive collaborative approach is essential to better define its role within the multidisciplinary management of NRSTS. Shared guidelines for PBT indications-based on the patient's age, estimated outcome, and tumor location-and centralization in high-level referral centers are needed to optimize the use of resources, since access to PBT remains a challenge due to the limited number of available proton therapy facilities., Competing Interests: The authors declare no conflicts of interest.
Published: 2024
Full Text: View/download PDF

20. Retrospective study of late radiation-induced damages after focal radiotherapy for childhood brain tumors.

Author: Cavatorta C, Meroni S, Montin E, Oprandi MC, Pecori E, Lecchi M, Diletto B, Alessandro O, Peruzzo D, Biassoni V, Schiavello E, Bologna M, Massimino M, Poggi G, Mainardi L, Arrigoni F, Spreafico F, Verderio P, Pignoli E, and Gandola L
Subjects: Child, Diffusion Tensor Imaging methods, Female, Follow-Up Studies, Humans, Male, Mental Status and Dementia Tests, Neurocognitive Disorders, Retrospective Studies, Abnormalities, Radiation-Induced diagnostic imaging, Brain Neoplasms radiotherapy, Gray Matter diagnostic imaging, Gray Matter radiation effects, White Matter diagnostic imaging, White Matter radiation effects
Abstract: Purpose: To study a robust and reproducible procedure to investigate a relation between focal brain radiotherapy (RT) low doses, neurocognitive impairment and late White Matter and Gray Matter alterations, as shown by Diffusion Tensor Imaging (DTI), in children., Methods and Materials: Forty-five patients (23 males and 22 females, median age at RT 6.2 years, median age at evaluations 11.1 years) who had received focal RT for brain tumors were recruited for DTI exams and neurocognitive tests. Patients' brains were parceled in 116 regions of interest (ROIs) using an available segmented atlas. After the development of an ad hoc, home-made, multimodal and highly deformable registration framework, we collected mean RT doses and DTI metrics values for each ROI. The pattern of association between cognitive scores or domains and dose or DTI values was assessed in each ROI through both considering and excluding ROIs with mean doses higher than 75% of the prescription. Subsequently, a preliminary threshold value of dose discriminating patients with and without neurocognitive impairment was selected for the most relevant associations., Results: The workflow allowed us to identify 10 ROIs where RT dose and DTI metrics were significantly associated with cognitive tests results (p<0.05). In 5/10 ROIs, RT dose and cognitive tests were associated with p<0.01 and preliminary RT threshold dose values, implying a possible cognitive or neuropsychological damage, were calculated. The analysis of domains showed that the most involved one was the "school-related activities"., Conclusion: This analysis, despite being conducted on a retrospective cohort of children, shows that the identification of critical brain structures and respective radiation dose thresholds is achievable by combining, with appropriate methodological tools, the large amount of data arising from different sources. This supported the design of a prospective study to gain stronger evidence., Competing Interests: The authors have declared that no competing interests exist.
Published: 2021
Full Text: View/download PDF

21. Secreting Germ Cell Tumors of the Central Nervous System: A Long-Term Follow-up Experience.

Author: Biassoni V, Schiavello E, Gandola L, Pecori E, Poggi G, Spreafico F, Terenziani M, Meazza C, Podda M, Ferrari A, Luksch R, Casanova M, Puma N, Chiaravalli S, Bergamaschi L, Cefalo G, Simonetti F, Gattuso G, Seregni EC, Pallotti F, Gianno F, Diletto B, Barretta F, and Massimino M
Abstract: Introduction: Due to the rarity of nongerminomatous germ cell tumors (NGGCT) with non-standard treatment as yet, we report retrospectively our 30 year experience with chemotherapy followed by craniospinal irradiation (CSI), plus a boost of whole ventricular irradiation (WVI)/tumor bed (TB), tailored to pre-radiation chemotherapy response., Methods: Between 1988 and 2016, 28 patients received four cycles of PEB (cisplatin/etoposide/bleomycin), then CSI, and two further PEB cycles. Between 1988 and1994, CSI was 25.5 Gy for patients in complete remission (CR), 30 Gy if in partial remission (PR) or metastatic, with a boost to TB up to 45-54 Gy. In the period of 1995-2010, the boost included WVI and any extra-ventricular tumor sites up to 45 Gy. After 2010, CSI was reduced to 25.5 Gy for all non-metastatic patients, and a boost was given only to TB up to 40.5/45.5 Gy, depending on patients' CR/PR status. After 2003, patients with alfafetoprotein (αFP) > 1000 ng/mL received intensified treatment, also including autologous stem cell transplantation., Results: Among 28 patients (23 males; median age 12 years, 6 metastatic), 25 responded to PEB, and three progressed (PD) after one to four cycles; 26 received radiotherapy obtaining 13 CR, 7 PR and 5 stable disease (SD), 1 PD; 6 (21%) died (5 for disease, 1 for pneumonia while in CR). Five-year overall survival (OS) and progression-free survival (PFS) were both 81%; 10 year OS and PFS 81% and 76%, respectively (median follow-up 11 years)., Conclusions: Survival for children with NGGCT, independently from disease extent, was encouraging. Further studies should elucidate which patients could benefit from reduced volume and dose irradiation.
Published: 2020
Full Text: View/download PDF

22. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma.

Author: Massimino M, Miceli R, Giangaspero F, Boschetti L, Modena P, Antonelli M, Ferroli P, Bertin D, Pecori E, Valentini L, Biassoni V, Garrè ML, Schiavello E, Sardi I, Cama A, Viscardi E, Scarzello G, Scoccianti S, Mascarin M, Quaglietta L, Cinalli G, Diletto B, Genitori L, Peretta P, Mussano A, Buccoliero A, Calareso G, Barra S, Mastronuzzi A, Giussani C, Marras CE, Balter R, Bertolini P, Giombelli E, La Spina M, Buttarelli FR, Pollo B, and Gandola L
Subjects: Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms mortality, Brain Neoplasms pathology, Chemoradiotherapy, Adjuvant mortality, Child, Child, Preschool, Cyclophosphamide administration & dosage, Disease-Free Survival, Ependymoma mortality, Ependymoma pathology, Etoposide administration & dosage, Female, Humans, Infant, Kaplan-Meier Estimate, Male, Neurosurgical Procedures mortality, Radiotherapy, Treatment Outcome, Vincristine administration & dosage, Brain Neoplasms therapy, Chemoradiotherapy, Adjuvant methods, Ependymoma therapy, Neurosurgical Procedures methods
Abstract: Background: This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III)., Methods: WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone., Results: From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable., Conclusions: In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports., (© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Published: 2016
Full Text: View/download PDF

23. Medulloblastoma treatment in a child on dialysis.

Author: Puma N, Biassoni V, Gandola L, Pecori E, Ardissino G, Paglialonga F, Indini A, Antonelli M, and Massimino M
Subjects: Child, Preschool, Humans, Male, Cerebellar Neoplasms therapy, Dialysis methods, Medulloblastoma therapy
Abstract: Managing patients who suffer from both cancer and end-stage renal disease is challenging because there is a paucity of data, especially for children. There are no published reports of adjuvant chemotherapy for medulloblastoma being used in children on dialysis. In this article we describe the case of an Italian 5-year-old boy on hemodialysis for chronic renal failure who presented with a desmoplastic medulloblastoma with extensive nodularity and nuclear β-catenin expression. The patient was treated with craniospinal irradiation after complete surgical resection, followed by six cycles of cyclophosphamide and vincristine. Vincristine was administered at the usual dosage for children with normal kidney function, cyclophosphamide was delivered after dialysis and over the course of the following day, starting with 50% of the commonly used dosage. This is the first case report of chemotherapy given during hemodialysis in a child with medulloblastoma. This treatment proved easy to administer despite the child's kidney disease and it maintained disease remission with no additional toxicity.
Published: 2014
Full Text: View/download PDF

24. Mid-trimester fetal-placental velocimetry response to nifedipine may predict early the onset of pre-eclampsia.

Author: Cobellis L, De Luca A, Pecori E, Mastrogiacomo A, Di Pietto L, Iannella I, Fornaro F, Scaffa C, Cobellis G, and Colacurci N
Subjects: Female, Fetus blood supply, Humans, Placenta blood supply, Pregnancy, Fetus drug effects, Nifedipine administration & dosage, Placenta drug effects, Pre-Eclampsia diagnosis, Pregnancy Trimester, Second
Abstract: The effect of nifedipine on fetal-placental blood flow at 22-24 weeks in patients with pregnancy-induced hypertension (PIH) was evaluated. Twenty patients with PIH were submitted to the Doppler evaluation of fetal-placental perfusion at 22-24 weeks. The systo-diastolic (SID) ratio and the pulsatility index (PI) of uterine, umbilical and middle cerebral arteries and systemic blood pressure were recorded before and 7 days after nifedipine administration (10 mg/ per os 3 times/day until delivery). Statistical analysis was performed with paired and unpaired t-test and the two-tailed Fisher exact test. Nifedipine significantly (p < 0.05) decreased the mean systolic pressure in all patients (from 146 to 135 mmHg): 8 patients developed pre-eclampsia (PE) complicated by fetal growth restriction (FGR) (PE group), whilst the remaining were only affected by PIH (PIH group). The gestational age at delivery, neonatal birthweight and 1- and 5-min Apgar scores were significantly (p < 0.001) lower in PE than in PIH women. Nifedipine treatment significantly changed the PI and S/D ratio (mean +/- SEM) of the uterine (PI from 0.66 +/- 0.01 to 0.51 + 0.01; SID ratio: from 2.00 +/- 0.09 to 1.79 + 0.05) and umbilical (PI: from 1.55 +/- 0.04 to 1.40 +/- 0.02; S/D ratio: from 2.45 +/- 0.09 to 2.31+/- 0.09) arteries and the middle cerebral PI (from 1.45 +/- 0.03 to 1.61 +/- 0.01) artery only in PIH, but not in PE patients. Fetal-placental blood flow changes after nifedipine may early identify patients at risk of PE.
Published: 2006

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

24 results on '"Pecori, E."'

1. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients

2. Neurological Symptom Improvement After Re-Irradiation in Patients With Diffuse Intrinsic Pontine Glioma: A Retrospective Analysis of the SIOP-E-HGG/DIPG Project

3. P06.01 Pediatric non-pontine diffuse midline glioma H3K27M mutant: a monoinstitutional experience

4. P14.77 Reduced dose craniospinal irradiation (CSI) is feasible for standard risk adult medulloblastoma (MBL) patients similarly to pediatric population

5. Pediatric intracranial ependymoma: correlating signs and symptoms at recurrence with outcome in the second prospective AIEOP protocol follow-up

6. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group

7. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma

8. Mid-trimester fetal-placental velocimetry response to nifedipine may predict early the onset of pre-eclampsia

9. Determinants of adenomyosis in women who underwent hysterectomy for benign gynecological conditions: results from a prospective multicentric study in Italy

10. EPENDYMOMA

11. HIGH GRADE GLIOMAS AND DIPG

12. ATYPICAL TERATOID RHABDOID TUMOUR

13. EPENDYMOMA

14. DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

15. Pediatrics Clinical Research

16. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma

17. Regression of ovarian enlargement in pharmacological ovulation induction

18. Dosimetric Comparison Between Proton and Photon Radiation Therapies for Pediatric Neuroblastoma.

19. Proton Therapy in Non-Rhabdomyosarcoma Soft Tissue Sarcomas of Children and Adolescents.

20. Retrospective study of late radiation-induced damages after focal radiotherapy for childhood brain tumors.

21. Secreting Germ Cell Tumors of the Central Nervous System: A Long-Term Follow-up Experience.

22. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma.

23. Medulloblastoma treatment in a child on dialysis.

24. Mid-trimester fetal-placental velocimetry response to nifedipine may predict early the onset of pre-eclampsia.

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

24 results on '"Pecori, E."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources